ImmunoScape operates in the biotechnology sector, specializing in advanced immune profiling solutions. The company focuses on identifying and profiling the immune response, particularly T cells, in infectious diseases and immunotherapy. ImmunoScape serves pharmaceutical companies, research institutions, and healthcare providers by offering cutting-edge immune profiling assays. These assays are designed to characterize and monitor key immune cell populations over time using 120 markers in one sample. This enables the simultaneous characterization of several immune cell subpopulations, such as T cells, B cells, NK cells, Basophils, HSCs, and myeloid cells.

ImmunoScape's business model revolves around providing these advanced profiling services to its clients, thereby generating revenue through service fees and long-term contracts. The company’s platform delivers key insights on antigen-specific T cells, which are crucial for studies involving immune checkpoint blockade, therapeutic and prophylactic vaccines, and T cell therapy. This empowers researchers and drug developers to discover novel vaccine, antibody, or cell therapy targets, evaluate treatment outcomes through longitudinal studies, design successful clinical trials through efficient patient enrollment, and uncover combinations of predictive biomarkers of disease or treatment efficacy.

Keywords: immune profiling, T cells, infectious diseases, immunotherapy, biomarkers, pharmaceutical research, vaccine development, cell therapy, immune response, biotechnology.